Fast-Tracking the Development of Monoclonal Antibodies
Monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs) have revolutionized modern medicine. In less than 40 years, these therapeutic agents have become instrumental in transforming the lives of patients with previously untreatable diseases, including autoimmune conditions and cancer.
Overcoming the Challenges
Although the field is rapidly expanding, the overall process of discovering and developing a single novel mAb can be slow. On average, it takes 17 years1 from initial research to market launch of any drug due to the challenges you encounter both in and out of the lab—challenges such as:
- Lead Identification and Optimization
- Process Scalability
- Instrument-To-Instrument Variability
- Data Reliability
- GMP compliance for transfer to manufacturing
Let’s Reduce the Lag Time
Automation platforms and precision instruments can streamline mAb and ADC development - from early-stage research to analysis - helping to ensure that a steady pipeline of therapeutic mAbs reaches patients faster. Let’s talk about how we can help you overcome manual barriers, minimize downtime and reduce time to market.
1Morris ZS, Wooding S, Grant J. The answer is 17 years, what is the question: Understanding time lags in translational research. J R Soc Med. 2011;104(12):510-520. doi:10.1258/JRSM.2011.110180
Learn More
Our Team is Ready to Help
Let’s talk about how we can help you overcome manual barriers, minimize downtime and reduce time to market.
